Motif Bio has had its Nasdaq IPO hopes crushed by an unreceptive market, leaving the late-phase antibiotic player with a hole in its spending plans.

The value of Neil Woodford’s Patient Capital Trust fell 10.8% as Circassia’s late-phase flop and the ongoing decline of Northwest Biotherapeutics hit home.

A week after microcap Tokai saw its shares plummet after the failure of its key Phase III prostate cancer candidate galeterone, the biotech has unsurprisingly…

With a confidentiality agreement in place, Sanofi says it is ready to move quickly to wrap up its pursuit of Medivation.

AstraZeneca has dropped 6 drug programs from its pipeline--with almost all the early-stage candidates being axed from its MedImmune biologics arms--in what is…

Unlikely IPO candidate Kadmon made it out in a tough IPO market amid swirling criticisms of its rather infamous current and former management, namely the…

Biogen’s long-standing CEO Dr. George Scangos is to step down from the company in “the coming months” as the Big Biotech looks for a successor.

It’s been a torrid first half for Aegerion Pharmaceuticals that began the year with a 25% cut to its staff, but the biotech is swinging the ax again--this time…